All In Biotech

Drug Trial Radar · NCT07655180

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Serum Virus Neutralizing Antibody Responses, and Pharmacokinetics of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Jun 8, 2026

Primary completion

Aug 15, 2026

Study completion Aug 15, 2026

Sponsor

Lead sponsor
Invivyd, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receiving VYD2311, or a COVID-19 vaccine, or a combination of VYD2311 and a COVID-19 vaccine in healthy participants. This research study will measure the amount of serum virus neutralizing antibodies produced in the blood (antibodies that block a virus from infecting cells) and pharmacokinetics of VYD2311 compared to a COVID-19 vaccine, when each is administered alone or concurrently. Pharmacokinetics is the study of how a drug moves through the body, including how it is absorbed (taken into the body), distributed (spread throughout the body), metabolized (broken down in the body), and eliminated (removed from the body), and how the body affects the drug.

Conditions

  • COVID-19

Interventions

  • COVID-19 mRNA vaccineDrug

    A one-time dose of COVID-19 mRNA vaccine will be administered by intramuscular injection.

  • VYD2311Drug

    A one-time dose of VYD2311 250mg will be administered by intramuscular injection.

  • Placebo (Normal Saline)Drug

    A one-time dose of normal saline (placebo) administered by intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6Time frame: Through 6 days after dose
  2. Assessment of systemic reactions solicited via e-diary through day 6Time frame: Through 6 days after dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Invivyd Investigative Site

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.